Abstract
The integrase enzyme encoded by the human immunodeficiency virus plays an integral role in the viral life cycle, but is as yet unexploited as a clinical drug target. Integrase processes the viral DNA in the cytoplasm, translocates to the nucleus, and catalyzes viral DNA insertion into the host genome. A wide variety of chemical structures inhibit integrase in vitro, yet few of these apparently promising compounds have demonstrated similar efficacy in vivo. Multiple binding targets have been identified for different integrase inhibitors. These targets include the integrase enzyme prior to substrate binding, the viral DNA substrate, and the preintegration complex consisting of oligomeric integrase and the viral DNA. Some known inhibitors are effective only in the presence of divalent manganese as the active site metal ion cofactor, whereas others do not discriminate between manganese and magnesium ions. Integrase inhibition in response to ligand binding at one of multiple sites renders derivation of a simple set of structure activity relationships challenging. Progress toward this goal is reviewed in the context of experimental and theoretical structural information about integrase.
Keywords: human immunodeficiency virus, integrase, structure activity relationship, inhibitors, structure-based drug design, docking, qsar
Current Medicinal Chemistry
Title: HIV-1 Integrase Inhibition: Binding Sites, Structure Activity Relationships and Future Perspectives
Volume: 10 Issue: 18
Author(s): A. L. Parrill
Affiliation:
Keywords: human immunodeficiency virus, integrase, structure activity relationship, inhibitors, structure-based drug design, docking, qsar
Abstract: The integrase enzyme encoded by the human immunodeficiency virus plays an integral role in the viral life cycle, but is as yet unexploited as a clinical drug target. Integrase processes the viral DNA in the cytoplasm, translocates to the nucleus, and catalyzes viral DNA insertion into the host genome. A wide variety of chemical structures inhibit integrase in vitro, yet few of these apparently promising compounds have demonstrated similar efficacy in vivo. Multiple binding targets have been identified for different integrase inhibitors. These targets include the integrase enzyme prior to substrate binding, the viral DNA substrate, and the preintegration complex consisting of oligomeric integrase and the viral DNA. Some known inhibitors are effective only in the presence of divalent manganese as the active site metal ion cofactor, whereas others do not discriminate between manganese and magnesium ions. Integrase inhibition in response to ligand binding at one of multiple sites renders derivation of a simple set of structure activity relationships challenging. Progress toward this goal is reviewed in the context of experimental and theoretical structural information about integrase.
Export Options
About this article
Cite this article as:
Parrill L. A., HIV-1 Integrase Inhibition: Binding Sites, Structure Activity Relationships and Future Perspectives, Current Medicinal Chemistry 2003; 10 (18) . https://dx.doi.org/10.2174/0929867033457043
DOI https://dx.doi.org/10.2174/0929867033457043 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Development of Natural Bioactive Alkaloids: Anticancer Perspective
Mini-Reviews in Medicinal Chemistry Quercetin in Cancer Treatment, Alone or in Combination with Conventional Therapeutics?
Current Medicinal Chemistry STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Iron Chelators in Cancer Chemotherapy
Current Topics in Medicinal Chemistry Modular Protein Engineering in Emerging Cancer Therapies
Current Pharmaceutical Design Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1- Oxopyrano[4,3-b][1]Benzopyrans and Nanogels for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Molecular Aspects of Resistance to Biological and Non-Biological Drugs and Strategies to Overcome Resistance in Colorectal Cancer
Current Medicinal Chemistry The Use of the Zebrafish Model to Aid in Drug Discovery and Target Validation
Current Topics in Medicinal Chemistry Artesunate Enhances the Antiproliferative Effect of Temozolomide on U87MG and A172 Glioblastoma Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC
Current Pharmaceutical Design Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Screening of Photosynthetic Pigments for Herbicidal Activity with a New Computational Molecular Approach
Combinatorial Chemistry & High Throughput Screening A Single Fas Gene Mutation Changes Lupus Onset, Severity, Location, and Molecular Abnormalities in Mice
Current Molecular Medicine Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Src Kinase Inhibitors: An Update on Patented Compounds
Current Medicinal Chemistry